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Tuesday, February 10, 2015 415acoefficient R 0.6 to either parent compound. The Schro¨dinger Suite 2014-2
was then used to prepare these molecules in a ready-to-dock format, including
all tautomers and isomers. The available crystal structure of MOPr with a
morphine replacing the crystallographic ligand at the orthosteric binding
site was used for docking of all these compounds with Glide 6.3 using the
XP scoring function. Following clustering of the top-ranked 10% compounds,
forty-five representative ligands from the most populated clusters were
selected for experimental testing based on visual inspection. As expected,
the majority of small molecules tested showed PAM activity at the MOPr
notwithstanding generally reduced activity values with respect to the parent
compounds. One molecule stood out from the others given its comparable
PAM activity to BMS-986121 and BMS-986122 in spite of a significantly
different chemical scaffold. Additional studies are ongoing to explore the po-
tential of this novel PAM of the MOPr as a lead for the development of new
therapeutics.
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As key targets for chronic pain, opioid receptors (ORs) are still at the forefront
of drug discovery efforts. In the hunt for opioid analgesics that are free from
adverse effects, recent high-throughput screening campaigns have focused on
identifying allosteric modulators, that is molecules that bind non-conserved
(allosteric) binding sites on the receptor, and modulate the potency and/or ef-
ficacy of ligands at the same (orthosteric) site as the endogenous agonist. Both
positive and negative allosteric modulators (PAMs and NAMs) of m-OR and
d-OR subtypes have recently been identified. While the recent crystal struc-
tures of ORs have revealed important details of ligand-receptor binding at
the orthosteric site, both the location of allosteric sites on these receptors
and the binding mode of opioid allosteric ligands are unknown. Here, we
applied all-atom metadynamics to efficiently study the binding of a PAM
and a NAM to the d-OR in the presence of the orthosteric agonist SNC-80
and an explicit lipid-water environment. The dynamics of the allosteric
ligands was enhanced by biasing the potential acting on the ligand-receptor
distance, and a contact map reflecting the ligand-receptor interaction. The
resulting energy landscapes show two deep energy minima for both the simu-
lated PAM and NAM, which correspond to the ligands acquiring specific
binding poses within two different nearby receptor pockets defined by trans-
membrane helices TM1, TM2, and TM7. Notably, the ligand binding poses in
the putative allosteric pocket that is closest to the orthosteric ligand overlap
with the allosteric site predicted by the fragment-based mapping algorithm
FTMAP. In spite of most ligand-receptor interactions being the same for
the simulated PAM and NAM within this pocket, there are important differ-
ences that are being tested experimentally through mutagenesis to assess their
functional role.
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Biased signaling, signaling through non G-protein linked pathways, occurs in
some GPCRs through mechanisms that are still not clear. Here we investi-
gated how an allosteric ligand for the cannabinoid receptor, CB1, could
induce such behavior, with the aim of identifying structural changes in the
receptor and gaining mechanistic insights underlying these phenomena. The
ligand, Org 27569, induces very unusual properties in CB1 - it increases
agonist binding to the receptor, yet simultaneously decreases G-protein
signaling while increasing biased signaling through beta-arrestin mediated
pathways. Using classical pharmacological binding studies, we find that Org
27569 binds to a unique and separate site than traditional antagonists, and
can act alone, without need for agonist co-binding. Similar analysis of consti-
tutively activating and inactivating mutations in CB1, which shift the equilib-
rium between inactive (R) and active (R*) receptor conformations, indicatethat Org acts by modulating the amount of active R* species present. To
determine the effect of Org on the structure of CB1, we carried out site-
directed fluorescence labeling (SDFL) studies. The SDFL results clearly
show that Org induces structural changes in CB1 that are different than those
caused by either antagonists or antagonists. While Org27569 blocks agonist-
induced movements at TM6 (consistent with its ability to block G-protein
signaling), it also enhances agonist-induced movements at H8, providing a
clue to its ability to induce biased signaling. Together, these results help
map the conformational dynamics involved in allosteric modulation and
biased signaling in CB1.
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The research presented details the creation of an activated state model of
the putative cannabinoid receptor, GPR55, based on the crystal structure of
CXCR4, a receptor with which GPR55 has high homology. Into this model,
analogs of the high throughput screen compound hit, (E)-3-(2-methoxy-
phenyl)-N-((4-(N-methyl-N-phenylsulfamoyl)phenyl) carbamothioyl)acryl-
amide (CID1792197), were docked. Of particular interest was the
synthetically novel GPR55 ligand, 6-(2-hydroxyethyl)-N-((4-(N-methyl-N-
phenylsulfamoyl)phenyl)carbamothioyl)-2-napthamide, in that it is a highly
bioactive analog of the parent molecule (CID1792197) . Both the novel ligand
and its parent scaffold mimic the shape of lysophosphatidylinositol (LPI), the
endogenous GPR55 ligand. Prior work in this lab established that the GPR55
binding pocket accommodates ligands with an inverted ‘‘L’’ or ‘‘T’’ shape,
having long, thin profiles that can vertically penetrate deep in the receptor,
while their broad upper regions occupy a horizontal binding pocket near the
receptor’s extracellular loops. Key interactions currently known to exist be-
tween ligands and the GPR55 receptor are hydrogen bonding with
K2.60(80), aromatic stacking with F3.33(102) and Van der Waals interactions
with M3.36(105), F5.47(190)and L7.35(270). The results of the current proj-
ect will facilitate the design and evaluation of third generation analogs as well
as a radiolabeled, high affinity ligand that will allow for optimal characteriza-
tion of the binding site interactions of the GPR55 receptor. [Support:
NS077347-A1, DA023204 and DA021358]
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G protein-coupled receptors (GPCRs) play important roles in signal transduc-
tion and represent about half of the drug targets. Accumulating evidence sug-
gests that GPCRs exist and function not only as homomers but as heteromers as
well. Coimmunoprecipitation and fluorescence resonance energy transfer
(FRET) results have provided evidence for heteromerization of D2-CB1
receptors in co-transfected cell lines. Besides, co-localization of CB1 and D2
receptors in the somata and dendrites of striato-pallidal GABA neurons and
cortical-striatal glutamate terminals has been demonstrated. Studies have
shown that homomeric D2 and CB1 receptors are Gi/o coupled able to inhibit
upon stimulation the forskolin-induced adenylyl-cyclase activation leading to a
decrease in cAMP levels. However, stimulation of the CB1 receptor upon
the co-expression of D2-CB1 receptors in cell lines increased cAMP levels
presumably because CB1 receptors switch their specificity to becoming
Gs-coupled when complexed with the D2 receptor. In this study, we utilized
Xenopus laevis oocytes as a heterologous expression system in which G
protein-sensitive inwardly rectifying Kþ (GIRK) channels are co-expressed
with GPCRs. Stimulation of GPCRs with specific ligands activates GIRK chan-
nels via the betagamma subunits of the G proteins (Gbg). The GIRK channel
current is monitored by two-electrode voltage clamp (TEVC) to access receptor
activity. We have found that stimulation of homomeric D2 and CB1 receptors
increases the GIRK currents. This increase could be blocked by pertussis toxin
(PTX) that specifically ADP-ribosylates Gi/o. Overexpression of Gs in Xeno-
pus oocytes biases signaling to couple Gs coupled receptors to GIRK channels
via Gbg. Using this approach, we demonstrated that neither the CB1 nor the D2
homomeric receptors can couple to Gs. We are in the process of testing
whether the channel response of CB1 receptor ligands through the heteromeric
D2-CB1 receptors proceeds via Gs.
